Current processes for the production of recombinant adeno-associated virus (rAAV) are
inadequate to meet the surging demand for rAAV-based gene therapies. This article reviews …

Faster and more accurate analytical methods are needed to support the advancement of
recombinant adeno-associated virus (rAAV) production systems. Recently, biolayer …

The field of gene therapy using Adeno-associated viral (AAV) vector delivery is rapidly
advancing in the biotherapeutics industry. Despite its successes, AAV manufacturing …

Recombinant adeno-associated virus (rAAV) is a widely used viral vector for gene therapy.
However, these vectors have limited availability due to manufacturing challenges with …

Abstract Adeno‐associated virus (AAV), a widely used gene therapy vector, is a small,
nonenveloped virus that contains a single‐stranded DNA genome with a maximum length of …

Recombinant adeno-associated virus (rAAV) is a widely used viral vector for gene therapy.
Despite its clinical efficacy, the manufacturing of rAAV faces challenges in productivity and …

The production of recombinant adeno-associated virus (rAAV) for gene therapy via triple
transfection is a highly intricate process involving many cellular interactions. Each of the …

Recombinant adeno associated virus (rAAV) vectors have become popular delivery vehicles
for in vivo gene therapies, but demand for rAAVs continues to outpace supply due to low …

Lentiviral vectors are highly efficient gene delivery vehicles used extensively in the rapidly
growing field of cell and gene therapy to treat a wide range of diseases. Demand for …